Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.

Inclusion criteria

• Men and women between ≥ 18 years and ≤ 80. Women in fertile age should use contraceptive methods recommended by the Clinical Trial Facilitation Group (CTFG).
• ECOG (Eastern Cooperative Oncology Group) quality of life scale ≤ 2.
• Patients with hepatic metastases of colorectal carcinoma and insufficient hepatic remnant function to perform a major hepatectomy. This volume would be calculated by Positron emission tomography-Computed tomography (PET-CT) images or 64-channel multidetector CT.

In patients who have received preoperative chemotherapy, the estimate residual liver volume to be included in the study will be <40%.

Patients who have preserved liver function (Child ≤ B7 and International Normalized Ratio (INR) ≤ 2 in non-anticoagulated patients) and those who have not received chemotherapy, needs < 30% of residual volume to be included in the study.

• Patients should have signed informed consent.

Exclusion criteria

• Pregnancy or lactation period.
• Any condition that the investigators consider an unjustifiable risk in the patient.
• Severe comorbidities: American Society of Anesthesiologists (ASA) ≥ 4.
• Alterations in the hemogram and morphological alterations, evaluated by hematologist prior to administration of G-CSF.
• Liver function: Child ≥ B7 and INR ≥ 2 in non-anticoagulated patients. In anticoagulated patients the values will have to be reverse, prior to surgery.
• Patients who have not received research drugs in the last 30 days or in the period of 5 elimination half-life.
• In patients on chemotherapy treatment, G-CSF can not be administered until 48 hours after the last administration of chemotherapy. Patients who have received Bevacizumab must wait 30 days since the last administration.
• In addition, all those aspects that prevent the patient from being part of the study, understand the rules, follow the instructions given, or other aspects.